Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MDM4 | O15151 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2438222 | 0.87 | MAPT (0.36) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL2906720 | 0.85 | MAPT (0.39) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL1058528 | 0.83 | MAPT (0.39) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL1058524 | 0.83 | MAPT (0.38) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL2435295 | 0.82 | MAPT (0.37) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL2435292 | 0.82 | MAPT (0.38) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL3801396 | 0.81 | RECQL (0.38) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL2438220 | 0.81 | MAPT (0.36) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL2438216 | 0.80 | MAPT (0.37) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 | |
| SCHEMBL6449991 | 0.79 | USP2 (0.41) | ALDH1A1MAPTHDAC6USP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193227-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2012-06-05 | — | — | US | disclosed |
| US-20110003827-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2011-01-06 | — | — | US | disclosed |
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003827-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | ALDH1A1 2920/4885MAPT 2176/4885HDAC6 1172/4885 |
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | ALDH1A1 2920/4885MAPT 2176/4885HDAC6 1172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.